# The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

> **NCT02500680** · PHASE1 · UNKNOWN · sponsor: **Nova Immunotherapeutics Limited** · enrollment: 102 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** MER4101
- **BIOLOGICAL:** Inactivated Influenza Vaccine

## Key facts

- **NCT ID:** NCT02500680
- **Lead sponsor:** Nova Immunotherapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500680, "The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02500680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*